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Summary
OBJECTIVE: In Switzerland, fewer than 40% of hepatitis
C virus (HCV) infected individuals have been diagnosed.
The aim of this project was to analyse the distribution of
HCV cases in order to develop better detection strategies.
STUDY DESIGN: Historical data on the HCV-infected
population in Switzerland were obtained from published
literature, unpublished data and government reports. A dis-
ease progression model was used to age the infected pop-
ulation to 2015. The HCV distribution was then used to
identify 5-year age cohorts with the highest HCV prevalen-
ce. The estimated number of cases needed to screen within
an age cohort was calculated using the estimated viraemic
prevalence, removing the percent previously diagnosed.
RESULTS: In 2015, the median age of the viraemic HCV
infected population was 49 years, with 75% of the pop-
ulation born between 1951 and 1985. Random screening
of the general population could identify one new viraemic
HCV case per 159 persons screened, compared with tar-
geted birth cohort screening, which could identify one new
viraemic HCV case per 90–99 persons screened.
CONCLUSION: Considering only the direct cost of
screening and treatment informing tests, targeted screening
by birth cohort is more effective and cost effective than ran-
dom screening in the general population.
Key words: hepatitis C virus (HCV); screening; birth
cohort; diagnosis; Switzerland
Introduction
Globally, there is a growing need for effective diagnosis
and screening strategies targeting patients with hepatitis C
virus (HCV) infection. Despite frequent use, the success
of risk based screening falls short of its potential [1]. This
may be due in part to a patient’s hesitation to disclose their
current or prior risk status, or to a lack of knowledge of risk
status [2]. In 2013 the US Preventive Services Task Force
recommended birth cohort screening to compliment current
screening efforts among high risk populations [3]. A re-
cent study conducted by the Swiss Federal Office of Public
Health analysed the birth year distribution of all reported
HCV cases and concluded that 60% were born between
1955 and 1974 [4]. The present analysis sought to identi-
fy which birth cohort would require the least screening in
order to diagnose one new viraemic HCV infection. In ad-
dition, it compared the direct cost of screening several dif-
ferent birth cohorts.
Methodology
Historical estimates for anti-HCV prevalence (1.6%
[range: 0.8–1.8%]) [5, 6], age distribution, annual number
of newly diagnosed cases (1 310 anti-HCV) and total num-
ber of diagnosed cases alive (41 300 anti-HCV) [7] were
compiled from the literature and government sources. HCV
has been a notifiable disease since 1988, and the Swiss re-
porting systems have been previously well described [4].
The scope of the analysis was limited to HCV viraemic
cases, with a viraemia rate of 79.7% applied to anti-HCV
estimates [8]. A previously described disease progression
model was used to age the HCV-infected population to
2015, taking into account mortality and cure rates [9, 10].
Each year, the population was moved from one single-
year age cohort to the next to simulate aging. Results were
aggregated to 5-year cohorts for reporting. Additionally,
the model tracked diagnosed cases, assuming a constant
number of new diagnoses each year after 2011. By 2015,
approximately 39% of patients were estimated to be dia-
gnosed.
For the analysis of the number needed to be screened to
diagnose one viraemic case (NNS), the median age in each
five-year age cohort was selected and converted to a birth
year. The NNS was calculated by taking the inverse of the
viraemic HCV prevalence in each cohort, after accounting
for the diagnosis rate, as follows:
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The NNS to identify 50 or 75% of the HCV-infected popu-
lation was calculated by aggregating five-year birth cohorts
to achieve the desired cohort size, and then using the for-
mula above.
Costs associated with diagnosing (anti-HCV serology =
CHF 25 and HCV RNA = CHF 180) and informing treat-
ment (genotype testing = CHF 180) were collected by use
of official reimbursement rates [11].
Uncertainty analysis was completed using Crystal Ball, an
Excel add-in by Oracle. Beta-PERT distributions were used
to model uncertainty associated with all inputs. Monte-
Carlo simulation was used to determine the 95% uncer-
tainty intervals (UIs).
Results
The median age of the viraemic HCV-infected population
in 2015 was 49 years. Approximately 50% of this popula-
tion was born during 1961–1980 and over 75% were born
during 1951–1985 (fig. 1).
Number of individuals needed to be screened in order
to diagnose one viraemic case (NNS)
Screening of the general population at random could identi-
fy one case per 159 (95% UI 140–361) persons screened.
By focusing screening on the population born between
1961 and 1965 (17% of total cases), it is estimated that one
new case could be found for every 76 (95% UI 66–181)
persons screened (fig. 1).
Within the 1961–1980 cohort one new case could be found
per 90 (95% UI 78–201) persons screened, and within the
1951–1985 cohort one new case could be found per 99
(95% UI 87–226) persons screened.
The cost of diagnosing one new viraemic case was highest
when screening the general population (CHF 4 390, 95%
UI 3 905–9 435) and lowest when screening persons aged
50–54 years (CHF 2 305, 95% UI 2 065–4 935). When
screening the 50% cohort, costs amounted to CHF 2 645
(95% UI 2 355–5 430), and within the 75% cohort, costs
amounted to CHF 2 885 (95% UI 2 570–6 065).
Figure 1
Percent of cases by 5-year birth cohort, the number of individuals
needed to test in order to diagnose one viraemic case, and the
associated cost to diagnose one viraemic case by birth cohort of
interest.
Discussion
This analysis presents a variety of birth cohort screening
strategies alongside the NNS and associated cost of dia-
gnosis. The strategy with the largest impact would involve
the 1951–1985 cohort, which captures 75% of all infections
and would require screening of 99 persons to identify one
new case. By contrast, screening within the 1961–1965
cohort could identify one new case for every 76 persons
screened; however, this cohort only captures 17% of all vir-
aemic cases.
A unique feature of this analysis is the focus on viraemic
cases and the exclusion of the previously diagnosed pop-
ulation; however, this also results in a higher NNS. Non-
etheless, focusing on the undiagnosed viraemic population
provides a more realistic estimate of the costs associated
with identifying a truly new case, as this population will be
the focus for treatment intervention.
Considering the direct cost of diagnosis, these results sug-
gest that it is more cost effective to test populations with a
relatively high HCV prevalence as compared with the gen-
eral population. The same conclusion could also be applied
to high-risk populations (persons who inject drugs and men
who have sex with men), which is in line with previous
publications [4, 6].
One limitation of this study is the assumption of a uniform
diagnosis rate across all ages. In reality, the diagnosis rate
among older adults may be higher as a result of increased
health awareness and attendance at health visits [12], dis-
ease progression or the presentation of symptoms. Dia-
gnosis rates among a younger population may be higher
owing to risk-based screening.
Enhancing HCV detection rates is possible through tar-
geted screening of high-prevalence birth cohorts. Consid-
ering only the direct cost of screening and treatment in-
forming tests, screening within these birth cohorts is also
more cost effective than screening within the general popu-
lation. Screening within a larger birth cohort (for example,
the 75% cohort versus the 50% cohort) has the additional
benefit of identifying a large number of new cases, with
marginally higher cost (CHF 2 885 vs 2 645).
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Figures (large format)
Figure 1
Percent of cases by 5-year birth cohort, the number of individuals needed to test in order to diagnose one viraemic case, and the associated
cost to diagnose one viraemic case by birth cohort of interest.
Peer reviewed letter Swiss Med Wkly. 2015;145:w14221
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 4
